Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Stock Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Wall Street’s consensus is “Moderate Buy”: Five of seven analysts rate Unicycive Therapeutics a buy, with an average 12-month price target of $18.25 versus the recent share price of $4.55. However, targets have generally been reduced and ratings include one hold and one sell.
• The company remains financially challenged: Unicycive reported a quarterly loss of $0.06 per share, better than the expected $0.47 loss, but analysts forecast a full-year loss of $1.16 per share. The stock is trading below both its 50-day and 200-day moving averages.
• Legal and regulatory risks weigh on the outlook: Multiple law firms announced a securities class action alleging manufacturing-compliance issues contributed to a second FDA Complete Response Letter and a sharp stock-price decline. Institutional investors own about 40.4% of the company, while HC Wainwright continues to maintain a bullish long-term view.

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $18.25.

Several analysts recently commented on UNCY shares. Zacks Research upgraded Unicycive Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 19th. Guggenheim restated a "buy" rating and set a $25.00 price target (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th. Benchmark restated a "speculative buy" rating and issued a $15.00 price target (up from $13.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 20th. B. Riley Financial restated a "buy" rating and issued a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Unicycive Therapeutics in a research report on Friday, September 4th.

Unicycive Therapeutics Trading Down 3.2%

Shares of UNCY opened at $4.55 on Friday. The stock's 50-day moving average price is $5.12 and its two-hundred day moving average price is $6.27. Unicycive Therapeutics has a 12 month low of $3.93 and a 12 month high of $8.74. The company has a market capitalization of $126.72 million, a PE ratio of -2.60 and a beta of 1.83.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.41. Equities research analysts predict that Unicycive Therapeutics will post -1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Unicycive Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC bought a new position in shares of Unicycive Therapeutics during the 1st quarter worth approximately $161,000. Bank of America Corp DE increased its stake in shares of Unicycive Therapeutics by 19,327.6% in the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company's stock valued at $194,000 after acquiring an additional 29,378 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Unicycive Therapeutics in the 2nd quarter valued at $248,000. Seven Fleet Capital Management LP acquired a new position in shares of Unicycive Therapeutics during the 1st quarter valued at $367,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Unicycive Therapeutics during the 1st quarter valued at $940,000. 40.42% of the stock is currently owned by institutional investors.

Key Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $13 price target, substantially above Unicycive’s recent trading level. The firm raised several longer-term EPS forecasts, including estimates of $2.85 for fiscal 2028, $3.75 for 2029 and $4.98 for 2030, reflecting expectations for improving commercialization and profitability. Some near-term quarterly and fiscal estimates were also improved, although the company is still expected to post losses through fiscal 2027. HC Wainwright earnings estimates
• Neutral Sentiment: Unicycive appointed Meredith Manning, M.B.A., to its board of directors. The addition may strengthen the company’s governance and strategic expertise, but the announcement provided no immediate change to the company’s clinical, regulatory or financial outlook. Unicycive appoints Meredith Manning
• Negative Sentiment: Multiple law firms publicized a securities class action against Unicycive and certain officers, with a November 2, 2026 deadline for investors to seek lead-plaintiff status. The allegations concern the company’s use of a contract manufacturer that had been cited by the FDA for current good manufacturing practice deficiencies, allegedly without confirming compliance. The lawsuit claims the unresolved issues contributed to a second Complete Response Letter and a reported 39.1% one-day share-price decline. These are allegations and have not been proven in court. Unicycive shareholder class action alert
• Negative Sentiment: HC Wainwright’s separate report reduced its Q1 2027 EPS forecast to a $0.43 loss from a $0.31 loss, and another report indicated the firm cut its price target, adding a modestly negative near-term signal despite the continued Buy rating.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for patients with kidney disease. The company's lead product candidate is oxylanthanum carbonate, an oral phosphate binder being developed to treat hyperphosphatemia, or elevated phosphate levels, in patients with chronic kidney disease, including those receiving dialysis.

Oxylanthanum carbonate is designed to bind dietary phosphate in the gastrointestinal tract, helping reduce the amount of phosphate absorbed into the bloodstream.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.